Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Interspecies interaction reduces selection for antibiotic resistance in Escherichia coli

ABSTRACT: Supernatant from B. subtilis cultures was found to be inhibitory to E. coli MG1655 growth and reduce enrichment of nitrofurantoin-resistant strains in the presence of the antibiotic. Supernatant from six different supernatants with differential effects on E. coli growth was harvested and analysed to identify the protein component responsible for growth inhibition.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Bacillus Subtilis Subsp. Subtilis Str. 168

SUBMITTER: Ramith Nair

LAB HEAD: Carina Sihlbom

PROVIDER: PXD040869 | Pride | 2023-03-15

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

Interspecies interaction reduces selection for antibiotic resistance in Escherichia coli.

Nair Ramith R RR Andersson Dan I DI

Communications biology 20230327 1

Evolution of microbial traits depends on the interaction of a species with its environment as well as with other coinhabiting species. However, our understanding of the evolution of specific microbial traits, such as antibiotic resistance in complex environments is limited. Here, we determine the role of interspecies interactions on the dynamics of nitrofurantoin (NIT) resistance selection among Escherichia coli. We created a synthetic two-species community comprised of two variants of E. coli ( ...[more]

PMID: 36973402

Similar Datasets

TMT-based Study of Gene Expression Changes in Escherichia coli in Presence of Plasmids

Project description:The plasmids introduced into the E. coli cells affect the expression of chromosomal genes. Therefore we aimed at comparing the protein expression profiles of a strain not containing any plasmid with strains that do carry plasmids.

2021-12-14 | PXD014039 | Pride

Transcription profiling of E. coli BW25113 fhlAL/pCA24N-FhlA133 vs fhlA/pCA24N-FhlA in modified-complex 20 mM formate at 37A?C

Project description:Variant FhlA133 (Q11H, L14V, Y177F, K245R, M288K, and I342F) had eight- fold higher hydrogen production than FhlA wild-type under 30 min of anaerobic incubation in modified-complex 20 mM formate at 37ÂºC. The mechanism by which the FhlA133 mutations increase hydrogen production is by increasing the transcription of all of the genes activated by the native FhlA (FHL complex). Experiment Overall Design: Strains: E. coli BW25113 fhlA/pCA24N-FhlA wild-type and E. coli BW25113 fhlA/pCA24N-FhlA133 (Q11H, L14V, Y177F, K245R, M288K, and I342F). Experiment Overall Design: Medium: Modified-complex 20 mM formate Experiment Overall Design: 1 mL of overnight culture in modified - complex 20 mM formate + Cm 30 Âµg/mL was inoculated in 9 mL of fresh modified - complex 20 mM formate + Cm 30 Âµg/mL and incubated anaerobically at 37oC in 27 mL glass vials. Experiment Overall Design: Time: 30 minutes Experiment Overall Design: Cell type: Suspension

2009-12-19 | E-GEOD-13902 | biostudies-arrayexpress

Global protein expression profiles of laboratory isolated mutants of E. coli K12, MG1655

Project description:Resistance to the antibiotic mecillinam in Escherichia coli can be conferred by mutations in over 100 genes. In this study we compared the global protein expression levels in a number of mecillinam resistant mutants originating from E. coli MG1655 to the levels in the parental strain.

2019-07-29 | PXD007647 | Pride

TMT-based study of yeast metabolism and translation under nitrogen limitation

Project description:Tandem mass tag (TMT)-based relative quantification was used to study yeast metabolism under the stepwise reduction the nitrogen content in the growth medium.

2020-03-13 | PXD014962 | Pride

TMT and Label-Free Quantification of Yeast Mitochondrial and Cellular Proteome During Different Stages of Growth

Project description:Tandem mass tag (TMT)-based relative quantification was used in combination with the intensity-based absolute quantity estimation (IBAQ) to study of both yeast cells and isolated yeast mitochondria during fermentative growth, diauxic shift, respiratory growth.

2020-03-06 | PXD012802 | Pride

Proteome Changes in the Development of Chronic Human Papillomavirus Infection in Rwandan Women

Project description:What happens to the proteome when a high risk (HR)-HPV infection occurs, when it is cleared and when it becomes chronic was investigated.

2022-02-17 | PXD029798 | Pride

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

Project description:High-risk neuroblastoma (NB) often involves amplification of the neural MYC (MYCN) oncogene as well as mutations in ALK. Currently, high-risk NB presents significant clinical challenges, and additional therapeutic options are needed. Oncogenes such as MYCN and ALK result in increased replication stress in cancer cells, offering one such therapeutically exploitable option. Here, we followed up on earlier phosphoproteomic analyses that identified ATR activity in ALK-driven NB cell lines. We tested several ATR inhibitors, identifying BAY 1895344 as the most potent inhibitor of NB cell growth and proliferation. Using RNA-Seq, proteomics and phosphoproteomics we characterized the response of NB cells and tumours to ATR inhibition, identifying key components of the DNA damage response (DDR) as well as ATRX, MYCN, E2F and DCK among other ATR targets in NB cells. ATR inhibition with BAY 1895344 also produced robust responses in mouse NB models. Remarkably, a 2 week protocol combining ATR and ALK inhibition led to complete regression of NB tumours in two independent NB genetically modified mouse tumour models. These results suggest that NB patients, particularly in high-risk groups with oncogene induced replication stress, may benefit from inhibition of ATR as therapeutic intervention.

2021-11-02 | PXD027187 | Pride

Regulatory elements coordinating initiation of chromosome replication to the Escherichia coli cell cycle

Project description:Escherichia coli coordinates replication and division cycles by initiating replication at a narrow range of cell sizes. By tracking replisomes in individual cells through thousands of division cycles in wild-type and mutant strains, we were able to compare the relative importance of previously described control systems. We found that accurate triggering of initiation does not require synthesis of new DnaA. The initiation size increased only marginally as DnaA was diluted by growth after dnaA expression had been turned off. This suggests that the conversion of DnaA between its active ATP- and inactive ADP-bound states is more important for initiation size control than the total free concentration of DnaA. In addition, we found that the known ATP/ADP-converters DARS and datA compensate for each other, although the removal of them makes the initiation size more sensitive to the concentration of DnaA. Only disruption of the regulatory inactivation of DnaA (RIDA) mechanism had a radical impact on replication initiation. This result was corroborated by the finding that termination of one round of replication correlates with the next initiation at intermediate growth rates, as would be the case if RIDA-mediated conversion from DnaA-ATP to DnaA-ADP abruptly stops at termination and DnaA-ATP starts accumulating.

2023-05-12 | PXD036580 | Pride

Proteomics of cell-free patient-derived scaffolds from breast cancer identify clinically relevant imprinted proteins and cancer-progressing properties

Project description:Breast cancer is a heterogenous disease that is difficult to model in vitro. Frozen primary breast cancers were decellularised to generate patient-derived scaffolds which are used to model 3D growth for cancer cell lines. The cell-free cancer microenvironments in the patient-derived scaffolds influence breast cancer cell line phenotypes and enrich for cells with cancer stem cell characteristics. Growth in patient-derived scaffold cultures also influenced the expression of epithelial-to-mesenchymal transition-related genes, and several gene expression changes in the model could be associated to clinical parameters of the original tumors and corresponding patients. Previous studies also demonstrated that the relative protein composition in the cell-free cancers were related to tumor grade and proliferation in cancer cells, suggesting that the relative proteomic composition varies between individual microenvironments. Therefore, we decellularised a larger breast cancer cohort to better characterize the cell-free microenvironments and potentially link to clinical features of the tumors and patients, which could be used to identify novel processes and targets that could be used to better model the disease or targeted in drug discovery.

2024-04-18 | PXD042671 | Pride

Proteome re-allocation in amino acid supplemented S. cerevisiae using TMT-based quantitative proteomics

Project description:In recent years, more attention in systems biology has been given to the concept of protein constraints and the cell’s necessity to allocate its proteome between important processes. From this point of view, attempts to elucidate cellular maximum capacity of growth as a function of protein availability has been investigated. Elucidating the possibility of optimizing cell proliferation, by tailoring proteome allocation. To experimentally investigate this concept further we cultivated Saccharomyces cerevisiae in bioreactors with or without amino acid supplementation and performed proteomics to analyze global changes in proteome allocation, during anaerobic as well as aerobic growth on glucose. Analysis of proteomic data implies that proteome mass is mainly being re-allocated from amino acid biosynthetic processes into translation, in regard to absolute levels of change, accompanied by an increased growth rate during supplementation. Similar findings were obtained from both aerobic and anaerobic cultivations, and subsequently independent of the two examined metabolic states. Indicating the possibility of increasing growth rate through freeing up proteome mass and increasing proteome allocation towards translational machinery.

2020-08-05 | PXD018361 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data